Navigation Links
Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
Date:4/24/2013

SUMMIT, N.J., April 24, 2013 /PRNewswire/ -- As leaders across business, policy and academia gathered at the recent World Health Care Congress (WHCC) to discuss ways to improve the quality and cost of healthcare, experts in treatment adherence identified a common theme: a patient-centric adherence strategy will be critical to achieving success.

"Healthcare reform is placing greater pressure for cost-efficiencies in the delivery of patient care and, as such, healthcare companies need to integrate treatment adherence strategies at the center of their programs," said Lina Eliasson , Ph.D., lead clinical strategist with Atlantis Healthcare, a sponsor of WHCC.  "Many exciting programs presented by industry leaders assumed a high degree of patient adherence – but in reality, treatment nonadherence is an enormous problem that can undermine the successful outcomes of any plan."

A report from the New England Healthcare Institute estimates that nonadherence to medication contributes $290 billion annually in unnecessary costs – about 13% of the total US healthcare expenditure. The report also notes that adherence rates are lower among patients with chronic conditions (i.e., diabetes, heart disease) than among those with acute conditions.

The most popular topics during the three-day WHCC conference centered on improving cost, quality and access to patient care:

  • Impact of the Patient Protection and Affordable Care Act
  • Role of integrated care and its effect on bundled care packages
  • Tele-health and implications for providers and payors
  • Employee wellness/assistance programs

While all talks referenced adherence, the topic of medication adherence was not featured as a headline item on the agenda, reinforcing the need for greater visibility.

Dr. Eliasson believes treatment adherence will emerge as an essential component in delivering positive outcomes across these areas and beyond.  "An effective strategy that motivates patients to follow prescribed treatment or a recommended health plan will decrease medication waste and overall healthcare cost, lower readmissions, and improve patient outcomes."

Understanding Intentional Nonadherence 
According to Dr. Eliasson, healthcare companies also need to have a greater awareness of the role of intentional nonadherence within the patient population. Studies show the majority of patients who don't follow their treatments are doing so on purpose – they may not believe the treatments work or that the benefits outweigh the side effects. 

"These patients need more than reminder calls and pillbox alarms," said Dr. Eliasson. "They need specific strategies and education to change their beliefs about their illness – and to motivate them to manage their health for the long term."

For more information on treatment adherence in healthcare, visit www.atlantishealthcare.com.

To learn about the World Health Care Congress, visit www.worldhealthcarecongress.com

About Atlantis Healthcare 
Established in 1993, Atlantis Healthcare creates and executes tailored patient support programs and personalized interventions to address treatment adherence across a wide range of chronic and acute diseases, worldwide.  Led by one of the world's largest health psychology teams, our patient-centric approach is designed to improve health outcomes and deliver optimal value for all healthcare stakeholders. www.atlantishealthcare.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.  
Lina Eliasson 
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=112389


'/>"/>
SOURCE Atlantis Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets has ... Strategies - 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis ... global Dry eye market. The research answers the following questions: ... eye and their clinical attributes? How are they positioned in the Global ...
(Date:2/24/2017)... 2017  In conjunction with DURECT Corporation,s (Nasdaq: ... release, you are invited to listen to a conference ... on Tuesday, March 14, 2017 at 4:30 pm Eastern ... audio webcast of the presentation will be available by ... "Investor Relations."  If you are unable to participate during ...
(Date:2/24/2017)... , Feb. 24, 2017 Juan Monteverde ... Associates PC , a boutique securities firm headquartered at ... City , announces that a class action lawsuit ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" ... Company,s securities between July 23, 2015 and December 30, 2016, ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is here, ... predict that 47 percent of all jobs in the United States may be taken ... The day of the aggressive know-it-all who steamrolls over colleagues is drawing to a ...
(Date:2/24/2017)... ... 24, 2017 , ... With ProGlass Prism users now have the ability to ... control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position ... With ProGlass Prism users are given the tools and effects to generate a ...
(Date:2/24/2017)... ... 24, 2017 , ... The Radiology Business Management Association will select ... the annual Building Better Radiology Marketing Programs conference, held this year from ... Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Department of Justice jointly issued a letter to withdraw previous guidance ... with their gender identity. The guidance issued in May 2016 by the Obama ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
Breaking Medicine News(10 mins):